View Post

Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Alex Keown From: biospace.com Amgen provided $2 million to the nonprofit Lazarex Cancer Foundation to support an effort to improve minority patient access to the potentially life-saving drugs in oncology clinical trials. Amgen’s contribution will go to Lazarex’s IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participation and equitable …

View Post

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

In Clinical Trials by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing  a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, including metastatic cancers, human immunodeficiency virus (HIV) and graft-versus-host disease (GvHD) is pleased to announce that on November 23, 2018, it received FDA approval of its IND submission and is allowed to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast …

View Post

Novartis reports new positive data from MONALEESA trials

In Clinical Trials by Barbara Jacoby

From: drugdevelopment-technology.com Novartis has reported positive results from three pivotal Phase III MONALEESA trials evaluating kisqali (ribociclib) plus endocrine therapy in combination with endocrine therapy alone for the treatment of human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients with difficult-to-treat visceral disease. The results are based on subgroup analyses and demonstrated that kisqali plus endocrine therapy …

View Post

Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

In Clinical Trials by Barbara Jacoby

From: apnews.com Dec 8, 2018–Generon BioMed Holding Ltd. (Generon), announced today at the annual San Antonio Breast Cancer Symposium (SABCS), positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein, designed using Generon’s Dikine TM technology platform. Led by Principle Investigator Dr. John Glaspy, Estelle, Abe and Marjorie Endowed Chair in Cancer Research …

View Post

Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial

In Clinical Trials by Barbara Jacoby

By: Sarah Tilyou From: clinicaloncology.com Maintenance therapy with olaparib can reduce the risk for ovarian cancer progression and related death by 70% at three years, according to results of the phase 3 SOLO-1 trial.  The findings, which were presented at the ESMO 2018 Congress (abstract LBA7_PR) and published in The New England Journal of Medicine (2018 Oct 21. [Epub ahead …

View Post

IMpassion130: PD-L1 Immune Cells Predictive of Survival Outcomes in Advanced TNBC

In Clinical Trials by Barbara Jacoby

By: Andrea S. Blevins Primeau, PhD, MBA From: cancertherapyadvisor.com PD-L1 tumor expression predicted survival outcomes among patients with advanced triple-negative breast cancer (TNBC) treated with atezolizumab plus nab-paclitaxel in the IMpassion130 study, according to data presented at the 2018 San Antonio Breast Cancer Symposium in Texas.1 It was previously reported that the phase 3 IMpassion130 trial (ClinicalTrials.gov Identifier: NCT02425891) met …

View Post

CAR-T Trial for Triple-Negative Breast Cancer Under Way

In Clinical Trials by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com A phase 1 trial (ClinicalTrials.gov Identifier: NCT02706392) is underway at Fred Hutchinson Cancer Research Center to evaluate a chimeric antigen receptor (CAR) T cell therapy in patients with cancer who have receptor tyrosine kinase-like orphan receptor 1 (ROR1)-positive disease, including those with triple-negative breast cancer (TNBC). The trial progress and early data for patients …

View Post

Syros Announces New Preclinical Data on SY-1365 at San Antonio Breast Cancer Symposium

In Clinical Trials by Barbara Jacoby

From: businesswire.com SY-1365 Shows Synergistic Activity in Combination with Fulvestrant in HR-Positive Breast Cancer Cells Resistant to Treatment with a CDK4/6 Inhibitor, Supporting Ongoing Clinical Investigation of the Combination Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) …

View Post

DNAtrix’s Oncolytic Virus Expressing OX40 Ligand Treats First Patient in Recurrent Glioblastoma Clinical Trial

In Clinical Trials by Barbara Jacoby

Source: DNAtrix From: prnewswire.com DNAtrix, a leader in oncolytic virus immunotherapies for cancer, announced today the treatment of the first patient with DNX-2440, an oncolytic virus expressing OX40 ligand (OX40L). The first-in-human Phase 1 study is evaluating the safety and efficacy of DNX-2440, administered by Alcyone’s Microtip Cannula at the time of biopsy, to patients with recurrent glioblastoma for whom …

View Post

Legislature passes bill to improve access to cancer clinical trials

In Clinical Trials by Barbara Jacoby

From: dailylocal.com WEST CHESTER—A new law designed to improve access to clinical trials for Pennsylvanians battling cancer is heading to the governor’s desk, state Senator Andy Dinniman said. House Bill 126 unanimously passed the Pennsylvania Senate this week after receiving unanimous approval in the House earlier this year. The bill was amended to include language from Dinniman’s Senate Bill 576, …